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Objective: If the body fails to acclimatize at high altitude, acute mountain sickness
(AMS) may result. For the early detection of AMS, changes in cardiac autonomic function
measured by heart rate variability (HRV) may be more sensitive than clinical symptoms
alone. The purpose of this study was to ascertain if the changes in HRV during ascent are
related to AMS.Methods:We followed Lake Louise Score (LLS), arterial oxygen saturation
at rest (R-SpO2) and exercise (Ex-SpO2) and HRV parameters daily in 36 different healthy
climbers ascending from 2400m to 6300m altitudes during five different expeditions.
Results: After an ascent to 2400m, root mean square successive differences, high-
frequency power (HF2min) of HRV were 17–51% and Ex-SpO2 was 3% lower in those
climbers who suffered from AMS at 3000 to 4300m than in those only developing AMS
later (≥5000m) or not at all (all p < 0.01). At the altitude of 2400m RMSSD2min ≤ 30ms
and Ex-SpO2 ≤ 91% both had 92% sensitivity for AMS if ascent continued without extra
acclimatization days. Conclusions: Changes in supine HRV parameters at 2400m were
related to AMS at 3000–4300m Thus, analyses of HRV could offer potential markers for
identifying the climbers at risk for AMS.
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INTRODUCTION
When ascending to high altitude, the body needs to acclima-
tize to low atmospheric pressure and hypoxic hypoxia (Hackett
and Roach, 2001). If the adaptation process fails due to too
rapid ascent rate or susceptibility of the climber, one or more
of three illnesses may result: acute mountain sickness (AMS),
high altitude cerebral edema (HACE) or high altitude pulmonary
edema (HAPE). AMS is the most common of these problems
affecting 25% of those who ascend to altitudes of 1850–2750m
(Honigman et al., 1993), 42% at altitudes of 3000m (Hackett
and Roach, 2001) and as many as 75% among those attempt-
ing Mount Kilimanjaro (5984m) (Karinen et al., 2008). AMS is a
non-specific syndrome characterized by the presence of headache
and at least one of the following: gastrointestinal symptoms
(loss of appetite, nausea, and vomiting), insomnia, dizziness, and
weakness or fatigue. It is a self-limiting syndrome, which usu-
ally resolves in 1–2 days if properly treated (rest, descent to lower
altitude, medication etc.) but may sometimes progress to more
serious altitude illnesses such as HAPE and HACE (Hackett and
Roach, 2001; Imray et al., 2011).
The exact mechanism causing AMS is unknown, but a marked
increase in peripheral sympathetic activity is a common feature
of AMS (Kamimori et al., 2009) and may be involved in the
pathogenesis of HAPE (Mazzeo et al., 1998; Duplain et al., 1999;
West, 2004). Heart rate variability (HRV) reflects sympathetic and
parasympathetic cardiac autonomic nervous system regulation.
Several studies have shown a transient reduction in parasympa-
thetic and increased sympathetic activity during acute exposure
to hypobaric hypoxia (Zuzewicz et al., 1999; Sevre et al., 2001;
Saito et al., 2005; Hainsworth et al., 2007) which tended to be
reversed with acclimatization (Cornolo et al., 2004).
There is a need for a non-invasive, specific and convenient
method under field conditions for the detection of inadequate
acclimatization and impending AMS. The arterial oxygen satu-
ration (SpO2) measurement is useful in anticipating AMS (Roach
et al., 1998; Karinen et al., 2010) but use of pulse oximetry under
field conditions is susceptible to many disruptive factors e.g.,
temperature (Luks and Swenson, 2011). Reduction in parasympa-
thetic and increased sympathetic activity during acclimatization
and AMS at 3180–4559m altitudes have been shown in several
studies (Loeppky et al., 2003; Lanfranchi et al., 2005; Chen et al.,
2008; Huang et al., 2010). To the best of our knowledge, studies
onHRV conducted in the field at extreme altitudes (>5000m) are
still lacking, despite two studies at simulated altitude (Yamamoto
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et al., 1993; Wille et al., 2004). Therefore the purpose of this
study was to evaluate whether HRV is related to AMS during
ascent and provides new information on the changes in cardiac
autonomic function as measured by HRV and not limited to alti-
tudes between 2400 and 5000m, which are most frequent among
climbers, but also at extreme altitudes above 5000m under field
conditions.
MATERIALS AND METHODS
The study group consisted of participants in four different expe-
ditions to Denali (Denali 1, Denali 2), Shisha Pangma andMount
Everest. All subjects were informed about the objective of the
study and the experimental protocol. The Ethics Committee of
Tampere University Hospital, Finland, approved the study pro-
tocol, and all subjects gave informed consent prior to the mea-
surements, as stipulated in the Declaration of Helsinki. Thirty six
different healthy volunteers (2 women and 34 men) with an age
range of 24–45 years participated in this study. Subjects’ mean
age was 32 (SD 6) years, body mass index (BMI) 25 (3) kg/m2
and maximal oxygen uptake (V˙O2max) 59 (7) ml/kg/min. None
of the subjects had been exposed to an altitude above 1000m
within the 6 months prior to this study. They were all lowland
dwellers and recreational mountaineers, and during the expedi-
tions none had taken acetazolamide as an AMS prophylaxis. Two
climbers were taking regular medication for asthma but no one
was using oral steroids, salmeterol, sildenafil or nifedipin. All
expeditions were organized in April-May. Ascent profiles were
similar at sleeping altitudes, but three expeditions had faster
and two slower ascent rate. Before the expeditions, all members
underwent a medical examination including resting ECG and
flow volume spirometry. To examine their exercise responses and
to measure maximal oxygen uptake (V˙O2max), they performed an
incremental clinical exercise test on a cycle ergometer (Ergoline
800S, Ergoline GmbH, Bitz, Germany). They started cycling at
20W and work rate was increased stepwise 20W/min up to voli-
tional fatigue. A 12-lead ECG was obtained at rest before the
exercise, and during the exercise test. All subjects had a nor-
mal EKG and none developed arrhythmias during the exercise
test.
DATA COLLECTION DURING ASCENT
Autonomic cardiac function was assessed by analysis of R-R
intervals (RRI). In power spectral analysis of HRV total vari-
ability of RRI is divided into low and high frequency bands.
High frequency power (HF power, 0.15–0.40Hz) reflects cardiac
parasympathetic modulation and is influenced by respiration.
Low frequency power (LF power, 0.04–0.15Hz) reflects both car-
diac sympathetic and parasympathetic modulation. The ratio of
LF and HF powers (LF/HF) has been reported to reflect sympa-
thovagal balance. RMSSD is the square root of the mean squared
differences of successive RRI and it is considered to be an index of
cardiac parasympathetic modulation (Task Force, 1996).
In the present study, HRV and SpO2 data were collected every
day during ascent at altitudes of 2400, 3000, 3500, 4300, 5000, and
5300m in all expeditions, and up to 5600 and 6300m at Shisha
Pangma. Data collection was continued until the base camp
of each mountain was reached. Measurements were done every
morning after 7–8 h night rest at that altitude by heart rate mon-
itors (Suunto T6, Suunto, Vantaa, Finland or S810, Polar Electro,
Kempele, Finland). HR recordings were made in the supine posi-
tion, after at least 15min of rest in the same position while each
subject laid quietly and breathed spontaneously. Then subjects
started their HR monitors and continued lying down for 3min.
The last 2min were chosen for data analysis. According to the
Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology (Task Force,
1996), the preferred duration of ECG recordings for comput-
ing short-term HRV components is 5min. The recording should
last at least 10 times the wavelength of the lowest frequency
bound of the investigated component (Task Force, 1996). Thus a
recording of approximately 1min is needed to assess the HF and
approximately 2min are needed to address the LF component. In
our study the duration of stationary RRI time series was 2min,
which should be adequate for the determination of the HRV
components evaluated (Koskinen et al., 2009). The arterial oxy-
gen saturation at rest (R-SpO2) was measured by finger oximetry
(Nonin Medical, Onyx 9500, Plymouth MN, USA) after 15min
rest while the subject was seated for an additional 2min. During
this period, R-SpO2 was observed four times at 15 s intervals and
the average R-SpO2 of these was recorded for data analysis. The
arterial oxygen saturation during exercise (Ex-SpO2) at altitude
was measured with a standard walking test (Karinen et al., 2010).
The climber walked and controlled his speed with the HR moni-
tor so that HR was approximately 150 beats/min during 3–5min
walking. Temperature varied between +20 and−15◦C and hands
were covered by mittens during walking, which ended inside a
tent. The inside temperature was mostly between +5 and 20◦C
because of extensive solar radiation or a stove. Immediately after
the cessation of walking, SpO2 was measured in sitting position
by finger oximetry four times at 5 s intervals during the first 15 s
of recovery starting immediately after stopping the exercise test.
The average of these values was recorded as Ex-SpO2 for data
analysis. We observed that SpO2 decreased 15 s after the exercise
began. During the first 15 s the SpO2 values remained very steady,
varying just 0–1% unit, thus quite accurately reflecting also SpO2
during exercise.
DATA ANALYSIS
Data processing and analysiswere performed after the expeditions
by Polar Precision Performance software (version 3.02.007) and
Kubios software (version 2.0) (Niskanen et al., 2004). Areas of
ectopy or artifact were identified and fixed by manual or auto-
matic error correction. Corrected segments were less than 5% of
the analyzed data. Analysis of HRV was done for stationary 2min
data segments. The power spectra were quantified by measuring
the area in two frequency bands. The HF2min power was cal-
culated for frequency band 0.15–0.40Hz and LF2min power for
frequency band 0.04–0.15Hz.
After the HRV and SpO2 measurements subjects were scored
according to the Lake Louise scoring (LLS) AMS system, which
include a self-report questionnaire related to the presence and
severity of symptoms and a clinical assessment (Hackett andOelz,
1992). The LLS was obtained by adding the score of the clini-
cal section to the self-report questionnaire. AMS was diagnosed
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FIGURE 1 | Ascent profiles of different expeditions and number of AMS
cases at different altitudes. Three climbers descended after 4300m
because of AMS. Measurements were made daily up to 5300m except on
Shisha Pangma, where measurements were made up to 5600m. AMS,
Acute Mountain Sickness; AMS∗, AMS at this altitude; AMS∗∗, AMS at some
other altitude.
according to a recent gain in altitude, the presence of headaches
and at least one of the following symptoms: gastrointestinal
(GI) upset, fatigue, dizziness or insomnia. To study, retrospec-
tively, whether HRV changes could have predicted AMS at higher
altitudes, we divided the study group into two groups: (1) If the
LLS was ≥ 3 at any altitude the subject was assigned to the AMS
group, and (2) If the LLS was ≤ 2 at every altitude measured, the
subject was assigned to the no-AMS group.
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STATISTICAL ANALYSIS
Continuous values are presented as means ± standard deviation
(SD). The frequency of parameters was assessed by x2 tests with
Yates’ correction. Differences between AMS and no-AMS groups
were compared by nonparametric t-test. Correlations between
the LLS and clinical and autonomic variables were assessed
by Pearson’s correlation. In all tests p ≤ 0.05 was considered
significant.
RESULTS
In total, 36 subjects were studied up to the altitude of 4300m.
Three discontinued because of AMS and the remaining 33 contin-
ued up to 5000 and 5300m altitudes. Five made all measurements
at 5600 and one at 6300m altitude. The Denali 1 and Shisha expe-
ditions reached the altitude of 5000m in 7 days (n = 16) and
the Denali 2 and Everest expeditions took 11–17 days to reach
the same altitude (n = 20) (Figure 1). Acute mountain sickness
developed in 24 out of 36 (66%) subjects at some altitude between
3000 and 5600m, including both women and 22 of 34 men, while
12 men (34%) did not get AMS at any altitude (no-AMS group).
There were 11 AMS cases in the faster group and 13 AMS cases
in the slower group. The groups did not differ in age, BMI or
V˙O2max. The descriptive data of participants and ascents for each
expedition are presented in Table 1 and Figure 1.
During this study, the daily ascent rates were mostly higher
than what is generally recommended (300m/day) but quite com-
mon for these mountains (range 400–1500m). In the no-AMS
group, RMSSD2min, LF2min and HF2min increased in the first few
days of the ascent. Above 3500m all HRV parameters decreased
while HR increased.
The number of AMS cases at different altitudes is presented in
Figure 1. Among those who suffered fromAMS, LLS scores varied
between 3 and 8. Most of the AMS cases occurred at 5300m (n =
10), and the prevalence of AMS increased significantly with alti-
tude and fast ascent rate on the day before onset (both p < 0.001)
(Figure 1). Headache and difficulty in sleeping were the most fre-
quent symptoms of AMS followed by GI symptoms, fatigue, and
dizziness.
At 2400m altitude, RMSSD2min and HF2min were lower
among those climbers who got AMS at lower altitudes
(3000–4300m) (n = 12) than in those who got AMS 3–7
days later at higher altitude (≥5000m) (n = 12) or not at
all (n = 12) (Table 2). HR2min, lnHF2min and RMSSD2min at
Table 1 | Demographic data (age, BMI, and V˙O2max) of the study
population.
Characteristic no-AMS AMS at some altitude All
(n = 12) (n = 24) (n = 36)
Age (years)∗ 30 ± 5 33 ± 7 32 ± 6
BMI (kg/m2) 24 ± 1 25 ± 4 25 ± 3
V˙O2max(ml/kg/min) 60 ± 4 60 ± 9 59 ± 7
There were no statistically significant differences in the basic characteristics
between no-AMS and AMS groups.
Values are mean ± SD. BMI, body mass index; V˙O2max, maximal oxygen uptake.
Table 2 | Resting heart rate (HR) and HRV parameters at 2400m
among the climbers who subsequently developed AMS at two
different altitude ranges, and those who had no subsequent AMS.
no-AMS AMS at AMS at ≥ 5000m
(n = 12) 3000–4300m (n = 12)
(n = 12)
HR (beats/min) 70 ± 9 82 ± 15* 62 ± 8*†
RMSSD (ms) 43 ± 25 21 ± 13* 48 ± 32†
lnLF (ms2) 7 ± 1 6 ± 1‡ 6 ± 1
lnHF (ms2) 6 ± 1 5 ± 2* 7 ± 2†
LF/HF 5 ± 4 6 ± 6 1.2 ± 1.1‡†
R-SpO2 94 ± 1 93 ± 2 94 ± 2
Ex-SpO2 91 ± 2 88 ± 3‡ 89 ± 3*
Values are presented in mean ± SD. (∗p < 0.05, ‡p < 0.01, difference between
AMS 3500–4300m vs. no-AMS groups and AMS ≥ 5000 m vs. no-AMS groups,
†p < 0.05, difference between AMS 3500–4300m vs. AMS ≥ 5000 m).
2400m correlated with the lowest altitude at which a climber suf-
fered AMS (AMS altitude) (Figure 2). There were no differences
between R-SpO2 at 2400m and later onset of AMS, but Ex-SpO2
was statistically higher in the no-AMS than the AMS group at
3000–4300m (p < 0.01) (95% CI 3 (1–5) and in the AMS at ≥
5000m group (p < 0.05). However, Ex-SpO2 did not correlate
with the AMS altitude (r = −0.028). At the altitude of 2400m
RMSSD2 min ≤ 30ms and Ex-SpO2 ≤ 91% both had 92% sen-
sitivity for AMS at 3000–4300m if the ascent continued without
extra acclimatization days (Figure 3). The sensitivity, specificity,
positive, and negative predicative values for chosen cut-off values
are presented in Table 3.
DISCUSSION
Our most important finding was that subjects susceptible to AMS
had lower HRV before the clinical manifestations of AMS than
those who acclimatized well and did not get AMS. This is a new
finding and offers fascinating options for predicting AMS at high
altitude in field conditions.
The diagnosis of AMS is clinical, but some specific changes in
cardiac autonomic function measured by HRV have been esti-
mated to be more sensitive in the detection of the early signs
of AMS than clinical symptoms alone at high altitudes (Saito
et al., 2005). HRV is reported to decrease in absolute units
(Hughson et al., 1994; Bernardi et al., 1998; Kanai et al., 2001)
and LF/HF mostly increased when subject got AMS (Loeppky
et al., 2003; Lanfranchi et al., 2005; Chen et al., 2008; Huang
et al., 2010). There are, however, also opposite findings reported
about HRV (Koehle et al., 2010). However, studies conducted
in the field at high and extreme altitudes (>5000m) are still
lacking.
During mild sympathetic activation, the observed increase in
HR has been reported to be associated with an increase in LF
power (Elghozi and Julien, 2007). However, with more intense
sympathetic stimulation, the increase in HR was reported to
be associated with an overall decrease in HRV, including its LF
component. Our present findings on changes in HRV values at
extremely high altitudes support this concept.
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FIGURE 2 | Negative correlation between HR and positive correlation
between lnHF, lnLF, and RMSSD at 2400m altitude and the
lowest altitude at which a climber got AMS (HR r = −0.743, p < 0.01;
lnHF r = 0.558, p < 0.05, lnLF r = 0.302, p > 0.05, RMSSD
r = 0.495, p < 0.05). no-AMS subjects datapoints are added at 5600m
level.
FIGURE 3 | Scattergram showing the distribution of values of RMSSD and Ex-SpO2 measured in 24 study subjects at 2400m in AMS and no-AMS.
The cut-off lines RMSSD2min ≤ 30ms and Ex-SpO2 ≤ 91% are for 92% sensitivity for AMS.
At 2400m the no-AMS group had higher HRV and lower
HR2min than the AMS group. The differences are not related
to differences in physical fitness in the AMS and no-AMS
groups because the basic maximum oxygen uptake did not differ
significantly between the groups (59 ± 11 vs. 60 ± 4, p > 0.05).
Furthermore, clear changes did not come in connection with
the ascent. However, in the no-AMS group HF2min tended to be
lower, while LF2min tended to be higher than in the AMS group.
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Table 3 | Sensitivity and specificity of chosen parameters at 2400m altitude for AMS at 3000–4300m.
Sensitivity (%) Specificity (%) Positive predicative value (%) Negative predicative value (%) 95% confidence interval
RMSSD2min ≤ 30 92 58 61 83 22 (5–39)
Ex-SpO2 ≤ 91 % 92 40 65 80 3 (1–5)
The physiologic significance of these findings remains uncer-
tain, but they do not directly support the earlier assumption that
AMS is simply connected with higher cardiac sympathetic activ-
ity. Rather, it seemed that a rise in cardiac sympathetic activity
would have been a protective phenomenon against altitude ill-
ness. However, altitude illness is a dynamic process. It may be that
as the AMS proceeds, HRV could further decrease. In other words,
changes in HRV were related to higher altitudes in all climbers,
but also notably to acclimatization and especially to failure to
acclimatize.
The present findings are still generally in agreement with
those of earlier studies and provide further insights into the
usefulness of HRV in the prediction of AMS under field con-
ditions. Several studies have shown that of SpO2 measure-
ments at rest (R-SpO2) and immediately after exercise (Ex-SpO2)
are predictors of AMS (Roach et al., 1998; Saito et al., 2005;
Burtscher et al., 2008; Karinen et al., 2010). Our study sup-
ports this. At 2400m altitude the Ex-SpO2 was statistically higher
in no-AMS group than AMS 3000–4300 group (p < 0.01) and
AMS ≥ 5000m group (p < 0.05). However, the SpO2 mea-
surements made by pulse oximetry under field conditions may
be susceptible to many disruptive factors (temperature, bright
light, cold fingers etc.) (Luks and Swenson, 2011). Therefore, it
is desirable to have an another parameter(s) to follow-up for
AMS susceptibility. Our findings support the possibility that
HRV could be used along with commonly measured physiolog-
ical parameters, HR and SpO2, clinical status and Lake Louise
questionnaire for AMS prediction in the short time period at
moderate altitudes. The altitude of 5000m was reached mainly
1–2 weeks after the measurements at 2400m and the ascent
rates per day were high just before reaching this altitude (700–
1500m/day). This may explain better the high prevalence of AMS
at 5000–5300m than a predominant vagal modulation at rest at
2400m.
The limitations of the present study include the relatively small
study group (n = 33) at extreme altitude (>5000m). The correla-
tions between HRV parameters and AMS are rather weak. Thus,
further studies with larger populations are needed to verify the
early changes in HRV between subjects with and without AMS
and/or other high-altitude illnesses, especially at extreme alti-
tudes, where the consequences of AMS, HACE, and HAPE may
dramatic. The length of measurements at high altitude may have
been too short to fully observe trends of changes in HRV vari-
ables between subjects with and without AMS or to capture other
HRV measures that could reflect more severe periodic breath-
ing. The differences in ascent rates, the places studied and the
altitudes studied may in part explain the differences between the
different results. Environmental and/or cardiovascular effects of
previous exercise may have been factors in the autonomic patterns
observed in subjects with AMS in our study. However, subjects
with and without AMS were studied under the same field con-
ditions and after similar recovery times as regards ascent. The
ascent rates during the expeditions were normal and widely used
in the mountains. Therefore, exercise and environmental fac-
tors may not explain the differences in autonomic cardiovascular
function observed in association with AMS in our study. HRV
is also partially influenced by respiratory rate and depth (Task
Force, 1996; Penttilä et al., 2001). In the HRV frequency spec-
trum, too, power in the entire frequency area, not just the HF
band, is decreased if the respiration rate increases (Task Force,
1996). Normally respiration rates will increase somewhat at high
altitude, but we do not know if the respiration rate is higher in
subjects with AMS than in subjects with no AMS. In this study,
the subjects were breathing spontaneously and some of the sub-
jects may have had breathing rate close to or below 0.15Hz,
which is the lowest boundary for the HF band. For this reason,
if altitude or AMS changed respiratory HRV, it cannot be exclu-
sively judged by changes in HF or LF/HF. Unfortunately, we do
not have sea-level HRV data for all subjects, so we cannot esti-
mate whether those climbers whose basic level of HF is higher
could acclimatize better than those whose HF level is lower at
sea-level.
Periodic breathing has reported to exist at high altitude mainly
during the sleep, but also in some extent during wake (Insalaco
et al., 1996; Fan et al., 2012). Because the breathing frequency
was not measured in our study, we cannot exclude it totally
(McMullen et al., 2012). However, the visual analysis of RRI
tachograms, AR spectrum and Poincare plots do not support the
existence of periodic breathing during the measurements. The
measurement periods were 2min so we can assume that any sig-
nificant periodic breathing was not seen when lying down during
this measurement period.
The strengths of the present study are that the rate of ascent,
altitude of origin and time of day of testing were known. Also,
within each group every climber had a similar diet, they were rel-
atively homogenous in their exercise capacity and they climbed
the same route on mountains over a short period of time with
essentially the same snow and weather conditions. Barometric
pressure varied from day to day but during measurements it was
stable.
In conclusion, at 2400m decreased RMSSD2min and HF2min
both predicted AMS in a few days if the ascent continued
without rest days. Autonomic cardiac response to increas-
ing altitude could be a low-cost non-invasive test to pre-
dict impending AMS and to help distinguish those who
are at risk for AMS and those who are acclimatizing well.
The trigger values typical for impending AMS await further
studies.
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